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The precise pathomechanisms of human autoimmune diseases are still poorly understood. However, a deepened understanding
of these is urgently needed to improve disease prevention and early detection and guide more speciﬁc treatment approaches.
In recent years, many new genes and signalling pathways involved in autoimmunity with often overlapping patterns between
diﬀerent disease entities have been detected. Major contributions were made by experiments using DNA microarray technology,
which has been used for the analysis of gene expression patterns in chronic inﬂammatory and autoimmune diseases, among which
were rheumatoid arthritis, systemic lupus erythematosus, psoriasis, systemic sclerosis, multiple sclerosis, and type-1 diabetes. In
systemic lupus erythematosus, a so-called interferon signature has been identiﬁed. In psoriasis, researchers found a particular
immune signalling cluster. Moreover the identiﬁcation of a new subset of inﬂammatory T cells, so-called Th17 T cells, secreting
interleukin (IL)-17 as one of their major cytokines and the identiﬁcation of the IL-23/IL-17 axis of inﬂammation regulation, have
signiﬁcantly improved our understanding of autoimmune diseases. Since a plethora of new treatment approaches using antibodies
or small molecule inhibitors speciﬁcally targeting cytokines, cellular receptors, or signalling mechanisms has emerged in recent
years, more individualized treatment for aﬀected patients may be within reach in the future.
Copyright © 2009 M. Kunz and S. M. Ibrahim. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Autoimmune diseases are a major cause of morbidity and
mortality in the industrialized world, aﬀecting 3–8% of
the population. In principle, autoimmunity develops after
breaking self-tolerance of the immune system, a process that
involvesmanydiﬀerentmoleculesandyetpoorlyunderstood
processes. It remains an open question whether bacterial or
viral pathogens contribute to the initiation of these diseases
as major causative agents [1, 2]. It is well documented
that early development and worsening of many chronic
inﬂammatory and autoimmune diseases such rheumatoid
arthritis(RA),psoriasis,andlupuserythematosus(LE)occur
in the context of bacterial infections [3, 4]. Although there
is signiﬁcant progress in the development of new treatment
modalities, the long-term outcome is often poor for many of
the aﬀected patients [5, 6]. Thus, a better understanding of
the pathogenesis of the autoimmune process is needed.
The spectrum of autoimmune diseases includes a large
variety of diseases such as RA, systemic lupus erythematosus
(SLE), psoriasis, multiple sclerosis (MS), type-1 diabetes,
Crohn’s disease (CD), and systemic sclerosis (SS) displaying
diﬀerent clinical features. However, beside the obvious
clinical diﬀerences there are also many clinical as well as
pathogenic overlaps. For example, RA, SLE, psoriasis, and
SS share chronic inﬂammatory joint disease, and SLE and
SS share comparable cardiac pathologies. Although for a
long time a matter of intensive debate, it appears that also
psoriasis may be regarded as autoimmune diseases, which
is supported by the ﬁnding that a signiﬁcant percentage of
psoriasis patients (up to 25%) suﬀer from additional joint
disease [7].2 Mediators of Inﬂammation
Inﬂammatory cytokines and chemokines appear to be
centrally involved in the pathogenesis of these diseases,
many of which had not been discovered until very recently
[8]. Here, IL-12 family members play a central role [9].
It is well established that in the presence of the common
inﬂammatory cytokine interferon (IFN)-γ, local antigen-
presenting cells (APCs) produce interleukin (IL)-12 leading
to diﬀerentiation of CD4+ T cells into IFN-γ-secreting T
helper type 1 (Th1) cells. In contrast, in the presence of IL-
4, CD4+ T cells preferentially develop into IL-4-, IL-5-, and
IL-13-producing Th2 cells. A strong maybe deregulated Th1
response is often found in autoimmunity. However, there is
compelling evidence for a third eﬀector CD4+ Th pathway
in autoimmunity. These so-called Th17 T cells produce IL-
17A and IL-17F, two cytokines not produced by either Th1
or Th2 CD4+ T cells [10]. A combination of transforming
growth factor (TGF)-β1 and IL-6, together with IL-23 leads
to generation of this CD4+ T cell subtype. After IL-23
stimulation, this new type of T cells produces a range of
inﬂammatory mediators including tumor necrosis factor
(TNF)-α, IL-6, granulocyte-macrophage colony-stimulating
factor (GM-CSF), CXCL1 and CCL20. Based on our current
knowledge, it appears that IL-17-producing T cells are
responsible for many of the inﬂammatory and autoimmune
responses once attributed to Th1 cells. Of these, TNF-α in
RA, CD and psoriasis, and IL-6/IL-6R in RA and CD have
been shown to be of clinical relevance [9, 11]. Recently,
the biology of IL-21 and its role in the pathogenesis of
autoimmunediseaseshasbeenreviewed[12].Indeed,aseries
of autoimmune animal models showed that IL-21 plays a
nonredundant role in autoimmunity and appeared to be
a common modulator of the adaptive immune response
towards self-tissue in diseases like RA, SLE, MS, and type-1
diabetes.
In order to achieve a more complete understanding
of molecules involved in autoimmune diseases, functional
genome and proteome techniques have been increasingly
applied in the last years [13–15]. Many of the current
studies signiﬁcantly contributed to our knowledge about the
pathogenesis of autoimmune diseases and will be detailed
below and be discussed in the context of the IL-23/IL-17
paradigm of autoimmunity.
2.Rheumatoid Arthritis
Rheumatoid arthritis (RA) is characterized by chronic
inﬂammation of the joints followed by reduced mobility
and destruction, ﬁnally leading to major disabilities in a
signiﬁcant percentage of cases. Overall, there is certain het-
erogeneity regarding clinical involvement of joints, presence
of autoantibodies in the peripheral blood and response to
treatment, suggestive for diﬀerent subtypes of the disease.
Although synovial tissues of joints are the main targets of
this disease, its systemic nature has fostered investigations on
gene and protein patterns in the peripheral blood [8, 16].
There is a signiﬁcant body of evidence that IL-23, IL-17
and IL-27 are involved in RA pathogenesis [9, 11]. Murphy
et al. demonstrated in an IL23/p19 and IL12/p35 knock-
out model of collagen-induced arthritis (CIA) in mice, the
corresponding mouse model of human RA, that IL-23 is
essential for the autoimmune inﬂammation of joints [17].
In these experiments, p19-deﬁcient mice were resistant to
the disease and unable to generate IL-17-producing CD4+
T cells (Th17 cells), while deletion of the IL12/p35 chain
even had disease promoting eﬀects, arguing for a disease-
protective role of IL-12 in this setting. Among various CD4+
T cell subsets, Th17 cells were identiﬁed as the exclusive
osteoclastogenic and thereby joint destructive T cell subset
among the known CD4+ T cell lineages inducing osteoclast
diﬀerentiation [18]. Moreover, IL-17 has been detected in
the synovial ﬂuid from RA patients and has been shown
to promote osteoclastogenesis by inducing the expression
of the Receptor Activator of NF-κBL i g a n d(RANKL) on
mesenchymal cells [19]. Similar ﬁndings were reported by
Ziolkowska et al. [20], demonstrating elevated levels of IL-
15 in synovial ﬂuid from RA patients and a strong corre-
lation between IL-15 concentrations and IL-17 levels [20].
However, IL-23 levels were not analyzed in this study. These
ﬁndings suggest that autoimmune arthritis may be regarded
as a Th17-type disease. In line with this, Chabaud et al.
demonstrated that RA synovial tissue explants produced IL-
17, IL-6, TNF-α and IL-1β [21]. Moreover, as demonstrated
by immunohistochemistry, a subset of inﬁltrating T cells
in RA synovium expressed IL-17. Additional supporting
evidence came from IL-17 knock-out animals that failed to
develop CIA [22]. Overall, the role of IL-17 in RA is less clear
cut than in mice. In particular, elevated levels of IL-17 in
peripheral blood of RA patients have not consistently been
described [9].
IL-27 is the most recently described member of the IL-
12 family. Its expression is induced by IFNs and it has been
suggested to be involved in early initiation of Th1 responses
[23]. IL-27 binds to a receptor composed of WSX-1/TCCR
and gp130, the latter of which serves as a common signal
transduction receptor for IL-6-related family members. IL-
27 suppresses Th17 development and mice defective for
IL-27 receptor WSX-1 showed increased susceptibility to
experimental autoimmune encephalomyelitis (EAE) and
showed higher levels of circulating Th17 cells. IL-27 inhibits
the IL-6 plus TGF-β-mediated diﬀerentiation of Th17 cells.
Together, IL-27 generally exerts anti-inﬂammatory activity
and may be regarded as a suppressor of autoimmunity.
A series of gene expression studies have been performed
to identify additional disease-related genes or gene patterns
in RA [24]( Table 1). Gene expression proﬁles from samples
of synovial tissue were analyzed in 21 RA patients and 9
osteoarthritis (OA) patients [25]. These analyses were per-
formed on an 18000 element cDNA chip, which speciﬁcally
contained immune regulatory genes. Gene cluster analysis
separated both diseases, with the group of OA patients also
containing some RA patients. Diﬀerentially expressed genes
between a high inﬂammation and a low inﬂammation group
inRAincludedgenesspeciﬁcforT-andB-cellssuchasCD20,
CD9, CD69, T cell receptor β and γ chain, proteases MMP1,
MMP3, chemokines IP-10, CXCR4, SDF1, transcription
factors STAT-1 and c-fos, and cytokines/cytokine receptors
IL-15, IL-6Rα, and IL-6Rβ. Many of these also showed
diﬀerential expression between RA and OA patients. MoreMediators of Inﬂammation 3
Table 1: DNA microarray studies on rheumatoid arthritis (RA), collagen-induced arthritis (CIA),multiple sclerosis (MS), and experimental
allergic encephalitis (EAE).
Disease Gene expression in aﬀected tissue Tissue Array type References
RA
CD9↑∗),C D 2 0 ↑,C D 6 9↑,Tc e l l
receptor β and γ chain ↑, MMP1 ↑,
MMP3 ↑,I P - 1 0 ↑,C X C R 4↑,S D F 1↑,
STAT-1 ↑,I L - 1 5↑,c - f o s↑,I L - 6 R α ↑,
IL-6Rβ ↑
Synovial tissue from RA and
Osteo-arthritis patients cDNA microarrays, 18000 probes [25]
IL-2 ↑,I L - 4↑,I L - 1 3↑,I L - 1 7↑,E G F↑,
bFGF ↑,I L - 1↑,I L - 1 5↑
Synovial ﬂuid from early onset
RA and other early synovitis
patients
Multiplex bead-based system,
Biosource International, Camarillo,
Calif, USA
[26]
CD14 ↑,d e f e n s i nα-1 and α-3 ↑,
ribonuclease 2 ↑, S100 A8 and A12 ↑,
HLA-DQB1 ↓
PBMC from RA and
osteoarthritis patients
Oligonucleotide microarrays,
10000 Probes
[29]
CD14 ↑, CD163 ↑, S100 A12↑,C D 1 3↑,
chemokine (C-C motif) receptor 1 ↑,
IL-1Ra ↑,C D 7 2↓, CD79b ↓,P K C θ ↓
PBMC from RA patients and
healthy controls
U95A microarrays, Aﬀymetrix,
12600 probes sets
[30]
CIA
Bsg ↑,A n x a 5↑,M m p 3↑,M m p 9↑,J u p
↑,T g f b 1↑, Il2rg, Cd53 ↑,c - f o s↓,S d c 4
↓,P r g 2↓
Inﬂamed paws of mice with CIA
and control mice
Mu11K oligonucleotide
microarrays, Aﬀymetrix, 11000
probe sets
[31]
MS
IL-1R ↑,I L - 8 R 2↑,I L - 1 1 α ↑,L - 1 7↑,
TNFR ↑, Filamin ↑,S M A D 6↑,M A G↓,
PLP1↓
Brain biopsies from MS patients
and controls
HuGeneFL oligonucleotide
microarrays, Aﬀymetrix, 7000
probe sets
[32]
ICAM1↑,C D C 4 2 ↑, RIPK2↑,I L 1 R 2 ↑,
CXCL2↑, ↑ MAD ↑, CDC25B ↓,D A X X
↓,B C L 2↓,N F A T C 3 ↓,E G F↓,E 2 F 5↓
PBMC from MS patients and
controls 1258 element cDNA microarrays [33]
BNIP3 ↑,2
 5
 OAS ↑,S T A T 1 ↑,
IFN-induced 17 kDa ↑,T R A I L↑,
CD69↓,c - j u n↓,c - f o s↓,ﬂ t 3l i g a n d↓,
IκBα ↓,I L - 8↓, IL-17R ↓,M K P 1↓,
PCNA ↓
PBMC of MS patients before and
under treatment with IFN-β
Mini-Lymphochip cDNA
microarrays, 12600 probes
[34]
MxA/MX1↑,I R F 7↑,M X 2↑,O A S 2↑,
IL15 ↑,I L 1 R N↑,I L 1 R A↑, CCR1 ↑,
ECGF1 ↑, EEF1D ↓,R P L 5↓
PBMC of MS patients before and
after treatment
HuFL microarrays, Aﬀymetrix,
8000 probe sets
[35]
EAE
Il1rn ↑, Tnfrsf1a ↑,I f n b 1↑,
interferon-induced 15 kD protein ↑,
interferon-inducible protein 1-8D ↑,
Ccl5 ↑, Scya-9, Cxcl10 ↑,T c r b↑, Cd53,
Lfa-1 (Itgb2) ↑, Flt3 ↓, Glud1 ↓,N t s r 2↓
Spinal cord biopsies from EAE
mice and controls
Mu11K oligonucleotide
microarrays, Aﬀymetrix 11000
probe sets
[36]
∗)Arrows indicate upregulated (↑) or downregulated (↓) gene expression in tissues/cells from aﬀected patients or animals compared with same tissues/cells
from control patients or animals.
detailed analyses of subgroups showed that STAT1 and genes
belonging to its pathway were upregulated in the high-
inﬂammation group.
Using a multiplex bead-based system for simultaneous
detection of 23 cytokines in small ﬂuid samples, a cytokine
proﬁle of synovial ﬂuid from early synovitis patients was
established [26]. This was possible due to the establishment
of a rapid access clinic in which patients with synovitis were
seen within the ﬁrst few weeks after onset of symptoms. The
36 patients with early inﬂammatory arthritis were followed
for 18 months and then assigned to their ﬁnal diagnostic
groups. 22 developed persistent inﬂammatory arthritis, 9
of which had RA. A series T cell-related cytokines such
as IL-2, IL-4, IL-13, IL-17, stromal-cell, and macrophage-
related cytokines such as EGF, bFGF, IL-1, and IL-15, was
upregulated in RA patients compared with patients with
otherearlysynovitis.Thesynovialcytokineproﬁleofpatients
with early synovitis developing RA was also signiﬁcantly
diﬀerent from that of patients with established RA. Early
onset RA patients had signiﬁcantly elevated synovial levels of
IL-2,IL-4,IL-13,IL-17,EGF,andbFGFwhencomparedwith
patients with established RA. The elevation of T cell-derived
cytokines in very early RA is of particular interest, since it
underscores the role of this cell-type in disease pathogenesis.
Th2-type cytokines such as IL-4, IL-13 may argue for a role
of Th2-inducing antigens in disease initiation [16]. Data
from multiplex cytokine analysis of serum from early RA
patients were compared with autoantibody activity. Patients
with high TNF-α,I L - 1 β, IL-6, IL-13, and IL-15 levels showed
antibodiestoseveralcitrullinatedepitopesandnativehuman
cartilage gp39 peptides, accompanied by development of
more severe disease [27, 28].4 Mediators of Inﬂammation
IL-10 is a potent anti-inﬂammatory cytokine that
has been shown to regulate endogenous proinﬂammatory
cytokine production in RA synovial tissue [37]. The authors
detected expression of both mRNA and protein for IL-10 in
RA and OA joints. Moreover, neutralization of endogenously
produced IL-10 in the RA synovial membrane cultures
resulted in a signiﬁcant increase in the protein levels of
proinﬂammatory cytokines tumor necrosis factor alpha
(TNF-alpha) and IL-1β. IL-20 and IL-22 are two new novel
members of the IL-10 family. IL-20 and its receptors were
expressed in synovial membranes and synovial ﬁbroblasts
derived from the synovial tissue of RA patients and CIA
rats, as demonstrated by immunohistochemistry [38]. It was
further demonstrated that administration of soluble IL-20
receptor type 1 in CIA rats reduced disease activity. Thus,
unlike IL-10, IL-20 may act as a pro-inﬂammatory molecule
in RA.
Bovin et al. studied gene expression signatures in PBMC
of RA patients [29]. Authors compared 8 RF-positive and
6 RF-negative RA patients, and 7 healthy controls. An
oligonucleotide-based DNA microarray was used, analyzing
gene expression of about 10000 genes. These analyses
revealed no signiﬁcant diﬀerences in gene expression pat-
terns of RF-positive and RF-negative patients. However,
diﬀerences were observed between RA and control subjects.
Higher expression in RA compared with controls was found
for CD14 antigen, defensin α-1 and α-3 (DEFA), fatty-
acid-Coenzyme A ligase, long-chain 2 (FACL), ribonuclease
2 (RNASE2), S100 calcium-binding protein A8, and A12
(S100A8 and S100A12). Expression of MHC class II, DQ β1
(HLA-DQB1) was reduced in RA patients compared with
healthy controls.
In a larger study conducted by Batliwalla et al. [30]
gene expression proﬁles of PBMC samples obtained from
29 RA patients and 21 normal control individuals were
analyzed. Out of 4500 genes expressed by PBMCs, 81
genes were identiﬁed with signiﬁcantly diﬀerent expression
between both groups. Of these, 52 were upregulated and
29 were downregulated in the RA group. The group of
upregulated genes comprised CD14 antigen, CD163, CD13,
S100 calcium binding protein A12, chemokine (C-C motif)
receptor 1 (CCR1) and interleukin 1 receptor antagonist
(IL-1Ra). Interestingly, many of the diﬀerentially expressed
genes correlated with number of monocytes in the two
study populations. A large fraction of these genes were
indeed speciﬁcally expressed at high levels in monocytes.
Downregulated genes comprised such as CD72 and CD79b.
Additionally, molecules associated with signal transduction
in lymphoid cells, such as lymphocyte-speciﬁc tyrosine
kinase, protein kinase C theta, death-associated transcrip-
tion factor 1, granzyme A, had lower transcript levels in
RA patients compared with healthy individuals. Together,
m o n o c y t e so rm o n o c y t es u b s e t ss u c ha sC D 1 4 + CD16+ cells
appear to play a role in RA, a ﬁnding which has also been
reported by others [39].
A more recent report emphasized the particular role
of IL-7 for RA [40]. IL-7 is a well-known cytokine of
the IL-2/IL-15 family and has been shown to be expressed
by stromal cells (e.g., in bone marrow and thymus),
epithelial cells, endothelial cells, ﬁbroblasts, smooth muscle
cells, and keratinocytes. The IL-7R is expressed by cir-
culating CD4+ and CD8+ T-cells, NK-T-cells and mono-
cytes, but not on human B cells. High levels of IL-
7 and IL-15 mRNA and protein expression have been
demonstrated in synovial tissue cells from RA patients
[41]. However, serum IL-7 values showed conﬂicting results
in a series of clinical studies, as did IL-7 levels in
healthy controls. IL-7 upregulates TNF-α production of
macrophages. An important role of IL-7 in RA synovial
tissueappearstobetheinductionofdiﬀerentiationofCD14+
monocytes into multinucleated, giant, bone-resorbing cells.
Thus, IL-7 may contribute to chronic inﬂammation and
joint destruction via T-cell mediated activation of osteo-
clasts.
In our own experiments on a murine model (DBA/1J
mice) of CIA, we used oligonucleotide microarrays with
11000 genes to determine gene expression proﬁles of
the inﬂamed paws at the peak of disease compared with
normal tissue [31]( Table 1). Overall, 223 genes showed
diﬀerentialexpression,ofwhich187wereupregulatedand36
downregulated. 95 of diﬀerentially expressed genes had well-
characterized full length sequences in databases, 128 were
unknown ESTs. The proﬁles identiﬁed supported current
disease models, as reﬂected by upregulated genes in disease
involvedinantigenprocessingandpresentation,forexample,
MHC were highly upregulated, and genes encoding other
immunerelated molecules, for example, complement, Ig
constituted a large group. Moreover, at least 3 diﬀerent
Mmps, Mmp 3, 9, and 13, were upregulated conﬁrming
the important role of these matrix degrading enzymes in
CIApathogenesis.Interestingly,Tgf-β1wastheonlycytokine
upregulated in inﬂamed paws, while other proinﬂammatory
cytokines such as Tnf-α, Il-6, Il-12, and Ifns remained
unchanged.
Mouse models are particularly powerful tools for genetic
studies of RA, because inbred mouse strains are geneti-
cally homogeneous, and therefore lack the complex genetic
heterogeneity of humans. Inbred strains also show some
degree of diﬀerential susceptibility to the disease because
of their genetic diﬀerences [42, 43]. In our genetic anal-
yses, sixteen genomic regions were identiﬁed to be asso-
ciated with disease in at least two RA mouse models,
some of which were overlapping between diﬀerent RA
mouse models [44]. One region is on chromosome 2,
and Cia2, Cia4, and Stia2 overlap at a 20 centi-Morgan
(cM) region containing the gene encoding complement
component C5, which appeared to be the most important
candidate gene for this region. In line with this, C5-
deﬁcient mouse strains have been reported to be resistant
to both collagen-induced arthritis and arthritis induced by
serum transfer [45]. A further QTL is on chromosome
15, 6 QTLs overlap at a 20cM genome region. These are
Cia26, Cia30, Cia31, Cia32, Paam1, and Pgia8.T h e4C I A
QTLs are derived from Eae2 and aﬀect disease through
complex interactions. Beside experimental autoimmune
encephalomyelitis, this region was also reported to be linked
to SLE.Mediators of Inﬂammation 5
3. SystemicLupusErythematosus
Systematic lupus erythematosus (SLE) is an autoimmune
disease with a strong genetic background [46]. There is
a sexual preponderance with more than 80% of lupus
patients being women. Skin lesions of SLE present as
small or medium-sized inﬂammatory macules or plaques
with a predominant involvement of sun-exposed areas. The
most prominent skin lesion is the so-called malar rash.
DisseminatedexanthematiclesionsarecharacteristicforSLE,
but rarely occur in patients suﬀering from the cutaneous
variants such as chronic discoid or subacute cutaneous
LE. Apart from skin, SLE aﬀects various internal organs
such as kidney, heart, lung, joints, and central nervous
system. Moreover, blood abnormalities such as leucopenia,
lymphopenia, thrombocytopenia, and complement (C1q,
C2, and C4) deﬁciency are common ﬁndings.
A signiﬁcant number of reports have addressed the
question of disease speciﬁc gene expression proﬁles in
SLE [47–49]( Table 2). Maas et al. found no signiﬁcant
diﬀerences in gene expression patterns of PBMC between
patients suﬀering from SLE, rheumatoid arthritis (RA),
multiple sclerosis (MS), and type-1 diabetes [50]. However,
autoimmune patients showed signiﬁcant diﬀerences in gene
proﬁles compared with control patients, which had received
inﬂuenzavaccination.Enhancedexpressionwasobservedfor
95 genes and reduced expression of 117 genes. Upregulated
genes involved receptor molecules, inﬂammatory molecules,
and signal transduction molecules. Reduced expression
was observed for genes with pro-apoptotic function (e.g.,
TRADD and TRAF). These ﬁndings are supportive for the
current concept of deregulated apoptosis in SLE.
At the same time, a microarray study addressed gene
proﬁles in PBMCs of 21 SLE patients and 12 controls
[51]. Expression of 375 cytokine- and chemokine-related
genes was analyzed using a cDNA microarray. Among the
genes upregulated in SLE were TNF/death receptor genes
such as TNFRII, and the death receptor ligand TNF-related
apoptosis-inducing ligand (TRAIL) (TNFSF10). Moreover,
mRNA expression for TRAILR3 (TNFSF10C) and TRAILR4
(TNFSF10D), two decoy receptors for TRAIL, was also
upregulated in SLE patients. Further transcripts with ele-
vated expression in SLE included IL-1α and β,I L - 1r e c e p t o r
2 (IL1R2), and IL1R accessory protein (IL1RAP), IL-8 and
its receptors IL8RA (CXCR1) and IL8RB (CXCR2), FcγR1
(CD64), urokinase R (CD87), PBEF, and PD-ECGF. Genes
with downregulated expression in SLE included IL-16 and
chemokine receptor CCR7.
Gene expression proﬁles of PBMCs from SLE and mul-
tiple sclerosis (MS), two clinically unrelated autoimmune
diseases, were analyzed in a further study [52]. A distinct
set of 1031 genes diﬀered in their expression in MS
versus controls and a set of 1146 genes diﬀered in their
expression in SLE versus controls. However, an overlapping
pattern between both diseases which diﬀered from controls
was identiﬁed, which involved apoptosis regulators such as
TRAF5, caspase 8, BCL2, IER3, and IL1B, pro-inﬂammatory
molecules, and genes involved in cellular proliferation and
immune response such as IL11RA, VEGF, and CD19. In line
with these ﬁndings, transgenic mice over-expressing CD19
generate spontaneous antinuclear antibodies and DNA auto-
antibodies [53]. SLE alone showed a characteristic pattern of
genes involved in DNA damage and repair.
The impact of treatment on gene expression was tested
in a study on six SLE patients suﬀering from lupus nephri-
tis. Half of the patients received intravenous methylpred-
nisolone plus cyclophosphamide, while the other half was
left untreated [63]. Interestingly, of the 151 diﬀerentially
expressed genes a majority was upregulated after treatment.
Genes belonged to functional groups of apoptosis, cell cycle
regulation, and DNA repair/replication, and some of the
genes are known to play a role in LE, such as Fc fragment,
immunoglobulin G, cytochrome c, p53, and CD22. Overall,
evidence was provided that common immunosuppressive
treatmentsinSLEmayhaveadirectimpactonmoleculesand
pathways involved in LE pathogenesis.
Xu et al. addressed the question of the mechanisms
maintaining autoreactive T cells in SLE [64]. These cells
are normally eliminated by functional inactivation (anergy)
and activation-induced cell death or apoptosis through
death receptor signalling. This study showed that peripheral
blood CD4+ T-cells from lupus patients were resistant
to activation-induced cell death. Subsequent microarray
analysis of cell death resistant cells identiﬁed a speciﬁc gene
cluster with high expression of cyclooxygenase-2 (COX-
2). COX-2 showed the highest increase (up to 39-fold) in
lupus T cells among the 591 diﬀerential genes analyzed after
exposure to anergy. In further analyses, COX-2 inhibitors
such as colecoxib and niﬂumic acid rendered resistant CD4+
T-cells susceptible to apoptosis. This was accompanied by
activated Fas signaling and decreased expression of c-FLIP.
Interestingly, when treated with a combination of anti-CD3,
anti-CD28 and interleukin-2, T cells from Cox-2-deﬁcient
mice were identical to controls with respect to activation-
induced cell death, suggesting a minor role for COX-2 in
survival of non-lupus T cells. Together, COX-2 appears to
play a central role in SLE pathogenesis and its inhibitors
may be used for the treatment of SLE. Indeed, it has been
shown that SLE patients proﬁt from treatment with COX-2
inhibitors [65].
A major leap forward in the understanding of lupus
pathogenesis was done when a series of independent
microarray studies identiﬁed a so-called interferon signa-
ture, indicating a signiﬁcant cluster of highly diﬀerentially
expressed genes, all inducible by type I interferons [47, 54–
56, 66–68]. Elevated levels of IFN-α were ﬁrst described in
1975 patients with various autoimmune diseases such as SLE
andRA[69].Moreover,IFN-αwasalsofoundinNZB/Wand
MRL/lpr/lpr autoimmune mice [70].
In the ﬁrst of these studies, Baechler et al. analyzed
gene expression proﬁles of peripheral blood cells of 48
SLE patients and 42 controls [54]. Overall, 161 genes
were identiﬁed as diﬀerentially expressed in patients as
compared to the control group. Many immune-related genes
showed upregulation in the SLE patients, including the IL-1
family members IL1B, IL1R2, and IL-1 receptor antagonist
(IL1RN).6 Mediators of Inﬂammation
Table 2: DNA microarray studies on systemic lupus erythematosus (SLE), psoriasis, and systemic sclerosis (SSc).
Disease Gene expression in aﬀected tissue Tissue Array type References
SLE
OASL ↑,L Y 6 E↑,M X 1↑,P R K R↑,
ICAM1 ↑,S C Y A 3↑,X I A P A F 1↑,L C K
↓,T C Rβ ↓,C D 1 C↓
PBMC of control and SLE
patients U95A microarray, Aﬀymetrix [54]
TNFSF10 ↑, TNFSF10C ↑, TNFSF10D
IL-1 α ↑,I L - 1α ↑,I L 1 R 2↑, IL1RAP ↑,
IL-8 ↑,C X C R 1↑,C X C R 2↑,F c γR1 ↑,
IL-16 ↓,C C R 7 ↓
PBMC of control and SLE
patients
cDNA microarray, 375 cytokine-/
chemokine-related cDNAs
[51]
TRIP14 ↑,O A S 1↑,T A P 1↑,T R A I L↑,
MX1 ↑,M X 2↑,X I A P A F 1↑,I F I T 4↑,
MCP-1 ↑,D C - L A M P↑,T C Rδ ↓,
DAP3 ↓
PBMC of SLE patients and
controls
U95A microarray, Aﬀymetrix,
12600 probes sets
[55]
IFN-ω ↑,I F I T 1↑,I F I T 2↑,I F I T 4↑,
OAS1 ↑,O A S 2↑,O A S L↑,L Y 6 E↑,
TCRα ↓,T C R δ ↓
PBMC of SLE patients and
controls
U95A microarray, Aﬀymetrix,
12600 probes sets
[56]
Psoriasis
S100A2 ↑∗), S100A7-A9 ↑,I L - 8↑,
DEFB2 ↑,C D 6 8↑,C D 4 7↑,E C G F 1↑,
ANXA1 ↑,K R T 1 5↓, MT1L ↓
Normal, univolved and involved
skin
U95A microarray, Aﬀymetrix,
12600 probes sets
[57]
S100A7 ↑, S100A9 ↑, S100A12 ↑,
FABP5 ↑,D E F B 2↑, MMP12 ↑,C D 4 7
↑,S T A T 1↑,T N X A↓,T I M P 3↓
Univolved and involved skin HuGeneFL microarray, Aﬀymetrix,
7000 probe sets
[58]
S100A7-A9 ↑,I L - 8↑,E C G F 1↑,P B E F
↑,S T A T 1↑,S C Y A 2↑,S C Y A 1 9↑,
SCYA21 ↑,S D F↑, CDKN1C ↓,
SCYA27 ↓,I T G B 1↓
Normal, univolved and involved
skin
U95A-E microarrays, Aﬀymetrix,
63000 probe sets
[59]
SSc
CALR ↑, COL15A1 ↑,N I D 2↑,C T G F
↑,F K B P 1 A↑,C D H 5↑,C D 1 4↑,C D 3 1
↑, FGF7, FGFR1, SCYA19 ↑,THY1 ↑,
CD53 ↑, IGHG3 ↑,B M P 1 0↓,W I F - 1↓
Involved, uninvolved and normal
skin
U95A microarray, Aﬀymetrix,
12625 probes sets
[60]
CENPE ↑,C D C 7↑,C D T 1 ↑,F G F 5 ↑,
TNFRSF12A ↑, TRIP ↑,N I C N 1↑,
SYT6 ↑,S M A D 1↓,I L - 1 5↓,C X C L 5↓,
FBLN 1 and 2 ↓
Diﬀerent subtypes of SSc patients Oligonucleotide microarrays,
44000 probes, Agilent Technologies
[61]
COLA7 ↑,C O L A 1 8↑,C D 4 4↑, MT1A
↑, MT1B ↑, MTIX ↑,D S P↑,P D G F C↑,
FGFRL1 ↑,V E G F B↓,S G K↓,P T X 3↓
Fibroblast cultures of SSc
patients and controls
Spotted oligonucleotide
microarrays, 16600 probes
[62]
∗)Arrows indicate upregulated (↑) or downregulated (↓) gene expression in tissues/cells from aﬀected patients compared with same tissues/cells from control
patients.
The most important ﬁnding was the presence of a
gene signature identiﬁed in half of the lupus patients,
which showed signiﬁcant overlap with that of IFN-α/β
stimulated PBMCs of normal controls. Twenty three out of
the mentioned 161 diﬀerentially expressed genes between
lupus and control patients were IFN-regulated. In a further
study on gene expression in pediatric SLE patients, gene
expression was measured in the PBMCs of 30 children
with SLE (approximately 60% female) and nine healthy
children [55]. Using statistical correction for multiple testing
according to Benjamini and Hochberg authors identiﬁed
33 genes, 26 of which were IFN-regulated. It was fur-
ther demonstrated that high-dose intravenous corticos-
teroid therapy, a common treatment of systemic lupus,
signiﬁcantly inﬂuenced the interferon gene signature. Both
studies showed highly overlapping patterns of interferon
signature.
Genes that have been identiﬁed as interferon-response
genes in one or both studies were IFIT1 (interferon-
induced with tetratricopeptide repeats 1), IFI44 (inter-
feron induced, hepatitis C-associated microtubular aggre-
gate protein), MX1 (myxovirus resistance 1), OAS1 (2 ,5 -
oligoadenylate synthetase 1), OAS2, and OASL (2 ,5 -
oligoadenylatesynthetase-likegene).Indeed,highIFNserum
levels were found in lupus patients and lupus-like symptoms
occur in IFN-α treated patients [71, 72]. Moreover, mouse
models with defective IFN receptors show a relatively benign
course of the disease compared with mice with wild-
type receptors [73]. The major producers of IFN-α are
plasmacytoid dendritic cells, which are enriched in skin
lesions of LE patients.
In line with these ﬁndings, plasma from lupus but not
from rheumatoid arthritis patients induced IFN-α regulated
genes in the WISH epithelial cell line, and plasma IFN-α lev-
els correlated with anti-RNA binding protein (RBP)-speciﬁcMediators of Inﬂammation 7
autoantibodies [74]. Moreover, in a study using antibody
microarrays for proteome analysis, lupus patients showed
enhanced expression of a set of 12 chemokines, many of
which are regulated by type I IFNs [75]. Among these were
MCP-1 (CCL2), MIG (CXCL9), IP-10 (CCL10), and I-TAC
(CXCL11).
Interestingly,theinterferonsignaturefoundinperipheral
blood of lupus patients was also found in kidneys of
aﬀected patients [76]. The authors examined global gene
expression proﬁles in kidney biopsies of patients with lupus
nephritis. Overall, 177 genes diﬀerentially expressed in lupus
kidneys compared with normal controls were identiﬁed.
After applying hierarchical gene clustering the IFN signature
was present in the form of an 11-gene cluster, of which seven
genes were IFN-regulated such as MX2, IFIT1, and ISG15.
Interestingly, another larger cluster contained genes having
roles related to ﬁbrosis (collagens I and VI, MMP7), which
might contribute to observed glomerulosclerosis.
Together, common characteristics of lupus appear to be
upregulation of members of the IL-1 family such as IL-1α
and IL-1β and IL1R2, of the TNF/death receptor family such
as TNF receptor II (TNFRSF1B), TRAIL (TNFSF10), and its
decoy receptors, and a gene signature of IFN-α/β-regulated
genes.
4. MultipleSclerosis
Multiple sclerosis (MS) is a chronic inﬂammatory demyeli-
nating disease of central nervous system generally aﬀecting
the white matter. MS aﬀects the ability of nerve cells
in the brain and spinal cord and the clinical picture is
heterogeneous. Almost any neurological symptoms may be
present, for example, aphasia, epilepsy, changes in sensation,
muscle weakness, diﬃculties with coordination and balance
and visual problems.
There is a signiﬁcant body of evidence indicating a
genetic predisposition to MS, a fact supported by twin
studies [77]. Concordance rates for monozygotic twins are
around 30%, whereas dizygotic twins show 2–4% [78].
MS linkage studies showed linkage to the human major
histocompatibility complex (MHC). In particular, it was
demonstrated that the HLA-DRB1∗15 allele confers a sig-
niﬁcant increase of risk for MS, and also other DR alleles
are predisposing for the disease, such as DRB1∗17. However,
based on SNP analyses, inﬂuence on MS pathogenesis may
also come from the MHC class I region [79]. It is well
understood that IFN-γ plays an important role in MS.
Elevated levels of IFN-γ have been described in experimental
allergic encephalomyelitis (EAE) and treatment of patients
with IFN-γ was deleterious to MS patients [80]. Genetic
polymorphisms in the IFNG gene have been associated
with MS. In a recent study, a gene polymorphism in
the 3  region of IFNG was shown to be associated with
susceptibility to MS at least in men [81]. The functional
relevance of this polymorphism has not yet been tested, but
linkage disequilibrium of this polymorphism with another
functional one in the IFNG gene might argue for its active
role in disease.
Recent research has shown that the IL-23/Th17 pathway
plays a role in EAE, the experimental counterpart of human
MS. This pathway might also be of relevance in humans.
In analyses of PBMC from MS patients, Vaknin-Dembinsky
et al. showed that monocyte-derived dendritic cells from
MS patients secrete higher amounts of IL-23 compared with
healthy controls but similar amounts of IL-12 [82].
Using in situ hybridization, Matusevicius et al. demon-
strated higher numbers of IL-17 mRNA-positive mononu-
clear cells (MNCs) in peripheral blood of 40% of MS
patients compared with healthy controls [83]. Interestingly,
patients with disease exacerbation had 3.5-times more IL-17
mRNA-positive MNC compared with patients in remission.
Moreover, MS patients had a signiﬁcant number of IL-17
mRNA-positive MNC in the CSF compared with control
patients suﬀering from other noninﬂammatory neurological
disease, indicating an enrichment or accumulation of Th17
cells at sites of inﬂammation in MS. CD4+ T cells isolated
from MS patients were stimulated in vitro with anti-CD3
and produced signiﬁcantly more IL-17 compared with T
cells from healthy controls. At the same time there was no
diﬀerence for IFN-γ secretion [82].
An earlier microarray analysis compared MS samples of
fresh frozen brain lesions obtained at early autopsy (1.5–
4.0 hours post mortem) from four MS patients and two
controls without nervous system pathology [32]. Moreover,
a comparison of two pathological stages of MS, acute and
chronic active lesions with inﬂammation versus chronic
silent lesions without inﬂammation, was performed. A
series of genes with at least a two-fold upregulation in
expression in at least three of the four MS samples clustered
together. Among the genes upregulated were IL-1 receptor
(IL1R), IL-8 receptor type 2 (IL8RB), IL-11 receptor α
(IL11RA), IL-17, and p75 tumor necrosis factor–receptor
transcripts (TNFR1B), indicating involvement of diﬀerent
pro-inﬂammatory cytokines in MS pathogenesis. Authors
alsoidentiﬁedexpressionoftwotranscriptionfactorsNF-IL6
and NF-κB, both with binding sites present in inﬂammatory
mediators such as TNF-α, IL-6, IL-8, interferon-γ (IFN-γ),
IL-2 receptor, and MHC class I and II genes. Genes encoding
proteins associated with myelin were decreased, including
myelin associated glycoprotein (MAG), proteolipid protein
(PLP1), oligodendrocyte-myelin glycoprotein (OMGP), and
GABA A receptor alpha (GABRA1). Genes elevated in
acute/active cases 1 and 3 compared with chronic silent
cases 2 and 4 included rearranged variable-joining constant
region (VJC) immunoglobulin, a MAP kinase kinase, insulin
growth factor-1, G-CSF, ﬁbroblast growth factor-12 (FGF-
12) and a FGF-2 homolog. IL-17 and TGF-β were elevated
17.7-fold and 17.9-fold, respectively, in the chronic silent
cases.
In the largest published study up to now, 72 patients
with MS versus 22 healthy control subjects were tested [33]
(Table 1). Gene expression was analyzed in PBMC, which
were separated into T and non-T populations. Authors used
a microarray with 1.258 genes, which included cytokines
and growth factors and their receptors, apoptosis regulators,
oncogenes, transcription factors, cell cycle regulators, and
identiﬁed 173 diﬀerentially expressed genes in T cells and8 Mediators of Inﬂammation
50 in non-T cells. In the T cell fraction, 25 genes were
upregulated, while 148 genes were downregulated in MS.
In the non-T cell fraction, 11 genes were upregulated,
while 39 genes were downregulated in MS. The top 30
diﬀerentially expressed genes in the T cell population
included upregulation of transcription factor 8 (TCF8),
a known transcription repressor for IL-2 in T cells, and
downregulation of chemokine receptor CCR5, and RGS14,
a known downregulator of signaling through G protein-
coupled receptors in MS. The top 30 diﬀerentially expressed
genes in the non-T cell fraction included upregulation
of cell division cycle 42 (CDC42), receptor-interacting
serine/threonine kinase 2 (RIPK2), IL-1 receptor, type II
(IL1R2), the chemokine MIP-2α (CXCL2) and intercellular
adhesion molecule-1 (ICAM1), and downregulation of cell
division cycle 25B (CDC25B), death-associated protein 6
(DAXX) and B-cell CLL/lymphoma 2 (BCL2). Since many
of the diﬀerentially expressed genes belonged to proprolif-
erative signalling mechanisms and either proapoptotic or
antiapoptotic functional categories, it was suggested that a
tightly controlled balance between resistance and suscepti-
bility toward apoptosis of lymphocytes and nonlymphocyte
immune cells might be important for MS pathogenesis.
In a treatment study, PBMC were collected for gene
expression proﬁles before and at regular intervals during
treatmentwithIFN-β andwerecomparedwiththebiological
response [34]. Authors used a Mini-Lymphochip cDNA
array [84] for expression proﬁling. Blood samples were taken
before and after treatment. The responder status of the
patients was deﬁned by a reduction of at least 60% in the
number of total Gadolinium-enhancing lesions in magnetic
resonance imaging (MRI) versus baseline [85], and a marked
reduction or absence of clinical disease activity. Overall,
six IFN-β treatment responders were compared with four
non-responders. By this means, 25 genes were signiﬁcantly
regulated, and an additional 87 genes showed interferon
response in vitro, together 112 genes with a signiﬁcant
regulation by IFN-β. Eighty-eight per cent of the genes
regulated ex vivo in responders were not regulated in the
non-responders. These genes included downregulation for
CD69, c-jun, c-fos, ﬂt3 ligand (fms-like tyrosine kinase 3
gene), IκBα, IL-8, and IL-17 receptor. Upregulated genes
included 2 5 OAS, STAT1, TRAIL, and an IFN-induced 17
kDa protein. IL-8 was markedly reduced in responders and
notinnonresponders.Itwasconcludedthattheevaluationof
the PBMC response assessed after a short treatment interval
might allow prediction of long-term treatment response.
However, this has to be tested in a prospective study.
Hong et al. presented a study using a microarray with
34 genes which were selected based on their role in inﬂam-
mation and their susceptibility to regulation by current MS
treatment agents IFN-β and glatiramer acetate (GA) [86]. In
vitro treated PBMC showed that interferon-inducible genes
were all upregulated after treatment with IFN-β, while the
expression of other selected genes encoding cytokines and
moleculesrelated toTcelltraﬃcking, activation and apopto-
sis was variably aﬀected. Similar regulatory eﬀects were seen
in ex vivo analyses of patients’ PBMC. In conclusion, this
technology might serve as a simple and sensitive assay for
detection of IFN-β neutralizing antibody, which may block
the regulatory properties of IFN-β on PBMC and may also
help to evaluate treatment responses in MS patients.
In a more recent approach, Sellebjerg et al. studied gene
expression in 10 MS patients after de novo treatment with
IFN-β, using DNA microarrays [35]. The primary aim of
their study was to identify genes whose expression could
serve as markers of the pharmacological eﬀect of IFN-β in
PBMCs. A secondary aim was to identify genes that may
predict treatment eﬀects of IFN-β. PBMC of 10 patients
were analyzed with an 8500 gene microarray, carrying
veriﬁed human gene transcripts. After the ﬁrst injection
of IFN-β, 285 genes out of 3428 detected genes showed
diﬀerential expression. Sixty-three of these were induced at
least two-fold, and 11 genes were reduced to 50% or less
of baseline expression levels. Among top upregulated genes
after treatment were MX1, interferon regulatory factor 7
(IRF7), MX2, OAS2, among top downregulated genes were
eukaryotic translation elongation factor 1 delta (EEF1D)
and ribosomal protein L5 (RPL5). A set of cytokines and
cytokine receptors such as IL15, IL1RN, IL1RA, CCR1, and
ECGF1 were also upregulated. Interestingly, there were no
long-lasting eﬀects of IFN-β on gene expression, as there was
no clear diﬀerence between baseline data and data obtained
before IFN injection within the second course of treatment
after three months, and data were not related to disease
outcome. Authors concluded that additional studies should
address the extent to which changes in the expression could
account for the clinical eﬀects of IFN-β treatment.
We used oligonucleotide microarrays to analyze gene
expression proﬁles of inﬂamed spinal cords of EAE mice at
onset and peak of disease [36]. In these experiments, seven
weeks old C57Bl/6 mice were immunized subcutaneously
with 150μg of rat myelin oligodendrocyte glycoprotein
(MOG) peptide. To identify the most relevant genes, the
threshold of diﬀerential expression was set to 4 folds. Overall
213 genes out of 11000 genes studied were diﬀerentially
regulated and 100 showed consistent diﬀerential regulation
throughout disease. Most genes, 166, were up-regulated and
only 47 were downregulated. Genes involved in antigen
processing and presentation, that is, MHC, and proteasome,
were highly up-regulated, and together with genes encoding
other immune-related molecules (i.e., complement compo-
nents, cytokines, and chemokines) constituted the largest
group of 72 genes. As expected, genes in the MHC locus
(EAE1 locus) were among this group, conﬁrming the central
role of MHC molecules in disease susceptibility. These
included molecules involved in antigen presenting such as
H2-Dr, H2-IA (alpha, d-haplotype), I-A (beta), and Qa-Tia
(all upregulated).
Upregulated genes further included IL-1rn antagonist
(Il1rn), tumor necrosis factor 2 receptor (Tnfrsf1a),
Interferon beta (type 1) (Ifnb1), interferon-induced
15kD protein (Isg15), interferon-inducible protein 1-8D,
Rantes (Ccl5), C10-like chemokine (Scya-9), macrophage
interferon-inducible protein IP-10 (Cxcl10), T-cell receptor
beta-chain (Tcrb), Cd53, Cd18 beta subunit (LFA-1)
(Itgb2). CNS-related genes were mostly downregulated such
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receptor (Ntsr2). Interestingly, of 104 genes with deﬁned
chromosomal locations 51 mapped to known EAE-linked
quantitative trait loci (QTLs) and might thus be candidate
genes for susceptibility to EAE. Interestingly, TNFR2 has
been suggested as a susceptibility gene in linkage analysis in
human MS patients [87].
5. Psoriasis
Psoriasis is a polygenic chronic inﬂammatory skin disease
with a signiﬁcant proportion of patients suﬀering from
additional joint involvement, which may ﬁnally lead to
destruction of joints and signiﬁcant functional impairment.
Interestingly, evidence is accumulating in recent years that
psoriasis might be a multisystem disease involving even
coronary arteries and heart [88, 89]. Testing a series of 32
psoriasis patients and an equally sized control population
authors found increased prevalence and severity of coronary
artery calciﬁcation (CAC) in psoriasis patients [88]. In
skin, both epidermal keratinocytes and inﬂammatory T-
cells are of central pathogenic importance, secreting an
aﬄuenceofinﬂammatorymediatorsactivatingAPCs,Tcells,
B cells, macrophages, and epidermal keratinocytes [90, 91].
In recent years, psoriasis is more and more regarded as an
autoimmune disease, although a speciﬁc autoantigen has not
been deﬁned up to now [92–94].
Recently, B. Nickoloﬀ presented a short overview about
cytokines with a suggested role in psoriasis pathogenesis
[91], focusing on the IL-23/Th17 pathway and its role
in psoriasis skin inﬂammation. As mentioned above IL-
23 sustains the development of pro-inﬂammatory, IL-17-
secreting CD4+ memory T cells (Th17 cells). In an earlier
report, diﬀerential expression of both IL-23p19 and IL-
12p40havebeendescribedinpsoriaticskinlesionscompared
with noninvolved skin, but no signiﬁcant diﬀerences were
observedfortheIL-12p35subunit,suggestiveforaparticular
role of IL-23 [95]. Moreover, strong immunohistochemical
staining of IL-23 was observed in the epidermis of psoriatic
lesional skin [96].
Epidermal thickening (acanthosis) of the skin is a
hallmark of psoriasis. It has been demonstrated that IL-
22, a well-known Th17 cytokine, mediates IL-23-induced
acanthosis in a mouse model of psoriasis [97]. In this study,
splenocytes from DO11.10 T-cell antigen receptor (TCR)
transgenic mice activated with ovalbumin peptide preferen-
tially produced IL-22, but not the related cytokines, IL-19,
IL-20 or IL-24, after IL-23 stimulation. It was further shown
that either IL-23 or IL-6 primed naive human CD4+ Tc e l l s
to diﬀerentiate into IL-22-producing cells. When injected
into mouse ear, IL-23 induced the production of both IL-
22 and IL-17, as shown by reverse transcriptase polymerase
chain reaction (RT-PCR) analysis. Finally, IL-23-induced
ear swelling was signiﬁcantly decreased in IL-22−/− mice
compared with the control mice, and epidermal acanthosis
and dermal inﬂammation were signiﬁcantly decreased in the
ears of IL-22−/− mice compared with wild-type controls.
Together, these ﬁndings argue for a particular role of IL-22
mediating epidermal acanthosis and tissue inﬂammation in
psoriasis after induction by IL-23.
Further inﬂammatory mediators were found in large-
scale genomic analyses using microarray technology. In an
earlier study, Bowcock et al. compared gene expression pat-
terns of lesional skin from 15 psoriasis patients with patterns
of normal skin from the same patients and normal controls,
using a microarray with 12625 gene probes [57]. Overall,
177 diﬀerentially expressed genes were identiﬁed. Signiﬁcant
upregulation in diseased skin was found for S100 family
members S100A2 and S100A7-9, which was conﬁrmed in
two independent reports [58, 98]. Moreover, this study
found signiﬁcant upregulation of well-known psoriasis-
related genes such as β-defensin 2, CD68, and cytokines
IL-8 (CXCL8), SCYA2 (MCP-1/CCL2), and platelet-derived
endothelial cell growth factor 1 in psoriatic skin lesions.
In a consecutive study with a microarray covering
63100 oligonucleotide probes, representing all known
genes at that time and expressed sequence tags [59],
the number of diﬀerentially expressed genes ran up to
1338 (Table 2). After applying supervised clustering of
diﬀerentially expressed genes for identiﬁcation of gene
patterns, a major cluster of 131 immune signaling genes
appeared. This cluster contained 19 chemokines, many
of which have not been described in psoriasis before.
This chemokine/cytokine group comprised IL-8, GRO-1
(CXCL1), small inducible cytokines SCYA2 (MCP-1/CCL2),
SCYA19 (macrophage inﬂammatory protein-3β/CCL19),
SCYA20 (macrophage inﬂammatory protein-3α/CCL20),
SCYA21 (secondary lymphoid-tissue chemokine/CCL21),
SCYA27 (cutaneous T cell-attracting chemokine/CCL27),
SCYB10 (interferon-γ-inducible protein 10/CXCL10) and
SDF (stromal cell-derived factor). It was further demon-
strated that many of these immune genes have common
upstream regulatory elements, as overlapping binding motifs
fortranscriptionfactorsc-Ets-2,NFκB,AP-1,andIRF2-ISRE
(interferon response factor 2-interferon-stimulated response
element) were identiﬁed in their promoters.
In order to analyze whether inﬂammatory activation
of immune cells in psoriasis is reﬂected by gene expres-
sion patterns in the peripheral blood, our group analyzed
gene expression proﬁles of PBMC from psoriasis patients
with severe generalized disease before and after treatment
[99]. Upregulation in the diseased stage was found for
IL-8 (CXCL8), COX-2, PBEF, ANXAIII, TNFAIP6, and
S100P. CDKN1C, also termed p57Kip2, was the only gene,
which showed signiﬁcant up-regulation in the cured stage.
Interestingly, CDKN1C acts as a cell cycle inhibitor in T-
cells [100]. Statistical analysis using support vector machines
showed that a combination of both IL-8 and CDKN1C was
able to diﬀerentiate between the two disease stages with
high prediction accuracy, which argues for a functional link
between both molecules.
Interestingly, microarray reports analysing PBMC or
psoriatic skin from psoriasis patients have not described
diﬀerential expression of IL-23, IL-17, or IL-22, although, as
mentioned above, these appear to play an important role in
psoriasis pathogenesis [91, 97]. Feasible explanations for this
might be that these cytokines were either not present on the
chips of earlier studies [57], or were not detected because
of expression levels below microarray sensitivity. In own10 Mediators of Inﬂammation
experiments using oligonucleotide microarray technology
to monitor disease course of rheumatoid arthritis patients
by analysis of PBMC gene expression, values of IL-23, IL-
17, and IL-22 were indeed generally below or only slightly
above detection limits (unpublished observation). However,
a signiﬁcant number of genes which may be induced by
IL-23 or IL-22 such as GRO-1 (CXCL1), S100A7, S100A8,
STAT3, IL-6, SCYA20 (CCL20), SCYA22 (macrophage-
derived chemokine/CCL22), and β-defensin 2 have been
identiﬁed in psoriasis microarray studies [57, 59, 98, 101].
6. Systemic Sclerosis
Systemic sclerosis (SSc) is a multisystem autoimmune
disease characterized by progressive sclerosis of the skin,
but often accompanied by involvement of internal organs
such as lung, heart and liver and gastrointestinal tract.
In order to identify genes or gene patterns involved in
this disease, diﬀerent approaches have been used. Earlier
studies used in vitro cultured ﬁbroblasts from SSc patients
and appropriate controls [102]. Using diﬀerential display
technology, enhanced expression of extracellular matrix
molecules like ﬁbronectin receptor, ﬁbrosin, nexin-1 and
insulin-like growth factor binding protein (IGFBP)-5 was
demonstrated in SSc. In another study, gene expression
proﬁles of skin biopsies from SSc patients analyzed by
microarray technology showed signiﬁcant diﬀerences of
gene patterns between aﬀected patients and healthy controls
[60]( Table 2). Gene cluster analysis identiﬁed functional
clusters named after major genes within these clusters, called
collagen I, B lymphocyte, cell adhesion and extracellular
matrix, smooth muscle, or T cell cluster, suggestive for a
role of these cells or particular cellular functions of these
cells in SSc pathogenesis. In order to further substantiate
these ﬁndings, gene patterns from SSc skin biopsies were
compared with those of cultured dermal ﬁbroblasts, B
lymphocytes, dermal microvascular endothelial cells, or
HS578T myoﬁbroblast-like cells. These analyses conﬁrmed
that many of the highly expressed genes in SSc skin also
showedsigniﬁcantexpressioninﬁbroblasts,endothelialcells,
and B cells. Among diﬀerentially expressed genes between
SSc and normal control skin were calreticulin (CALR),
collagens type V (COL5A2) and type XV (COL15A1),
nidogen 2 (NID2), CD14, CD31, VE-cadherin, S100A7,
and CD53. Cytokine or cytokine receptor patterns showed
high expression of CCR1, FGFR1, connective tissue growth
factor (CTGF), FGF7, and SCYA19 in biopsies from SSC
patients.
In a consecutive publication of the same group, an
update of these analyses was provided with a larger number
of patients suﬀering of distinct scleroderma subsets [61].
These included 17 patients with systemic sclerosis (SSc) with
diﬀuse scleroderma (dSSc), 7 patients with SSc with limited
scleroderma (lSSc), 3 patients with morphea, and 6 healthy
controls. In addition, authors found that distinct patterns
of gene expression separated patients with dSSc from those
with lSSc. Moreover, both could easily be distinguished from
normal controls. Diﬀerences in gene expression in diseased
versus normal skin included a series of collagen genes such as
COL5A2, COL8A1, COL10A1, COL12A1. Authors focused
on a 177-gene signature that was associated with severity of
skin disease in dSSc. Of these, 62 genes were expressed at
high levels, and 115 genes were expressed at low levels in the
patients with the highest skin score. These highly expressed
genes included cell cycle genes CENPE, CDC7 and CDT1,
FGF5, tumor necrosis factor receptor superfamily member
12A (TNFRSF12A) and TRAF interacting protein (TRIP).
Interestingly, only one cytokine, FGF5, was highly expressed
in this group. The low expressed genes included SMAD1, IL-
15, CXCL5.
In a study on early molecular events in SSc, gene expres-
sion proﬁles were analyzed in ﬁbroblasts from skin biopsies
taken from clinically uninvolved skin of 21 SSc patients and
18 healthy controls [62]. Authors used an oligonucleotide
microarray with 16600 probes. Gene ontology (GO) cat-
egories of collagen (cat. 5581), extracellular matrix (cat.
5201), and complement activation (cat. 6956) were enriched
with diﬀerentially expressed genes. Again, collagens such as
COL7A1 and COL18A1 (endostatin) appeared to play an
important role, together with COMP (cartilage oligomeric
matrix protein), CD44, and ﬁve metallothionein genes.
Overall, 71 diﬀerentially expressed genes were identiﬁed
with a calculated false discovery rate of 10 genes. Based on
these ﬁndings, authors suggested COL7A1 and COL18A1
as putative biomarkers for early onset of SSc. Interestingly,
a correlation between disease activity and serum COL18A1
levels has been described earlier in SSc patients [103].
Most signiﬁcantly decreased genes included serum and
glucocorticoid-induced kinase (SGK), VEGFB, and decay-
accelerating factor for complement (DAF). The group of
cytokines or cytokine receptors included upregulated genes
forPDGFC, FGFRL1, anddownregulated genes forPDGFRL
and VEGFB.
Pulmonary ﬁbrosis is a hallmark of SSc. Bronchoalveolar
lavage ﬂuid (BAL) from patients suﬀering from pulmonary
sarcoidosis, pulmonary ﬁbrosis associated with SSc, or
idiopathic pulmonary ﬁbrosis (IPF) was analyzed in a
recent proteome approach [104]. BAL ﬂuid proteins were
separated by 2D gel electrophoresis and identiﬁed by
mass spectrometry. Enhanced expression of proteins in SSc
compared with IPF was demonstrated for α1-B glycopro-
tein, complement C3β, α1-antitrypsin, and haptoglobin β.
Proteins with enhanced expression in SSc compared with
sarcoidosis included prothrombin, thioredoxin, peroxisomal
antioxidant enzyme (AOPP), calgranulin, and thioredoxin
peroxidase 2. Thrombin acts as a mitogen for ﬁbroblasts
and enhanced thrombin levels had been demonstrated in SSc
BAL ﬂuid in earlier reports [105]. Thioredoxin was highly
expressed in a rat model of oxidant-induced pulmonary
ﬁbrosis [106].
Taken together, the presented genome and proteome
analysesaresuggestiveforanimportantroleofﬁbroblasts,B-
cells, T cells, endothelial cells and the coagulation system in
the pathogenesis of SSc. Interestingly, only a few cytokines or
chemokines have been detected in skin lesions or ﬁbroblasts
by microarray technologies and therefore appear to play a
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7. Pros andCons of Genomics and
Proteomics Technologies
DNAmicroarrayandproteomicstechnologiesareamainstay
of many of the above mentioned studies, and have indeed
provided a plethora of new information regarding genes
involved in autoimmune diseases. However, there are several
inherent limitations in genomcis and proteomics studies.
DNA microarray technology started in the early nineties of
the last century and has since developed rapidly. At present,
oligonucleotide and cDNA microarrays cover all known
genes (more than 35000). In an earlier report by Lockhart
et al. [107], it was demonstrated that oligonucleotide DNA
microarrays are able to measure mRNA molecules within
a wide linear range, detecting as little as a few molecules
per cell. The detection lower limit of current microarray
technology is around ten copies of mRNA per cell [108].
However, low abundance genes such as transcription factors
and some cytokines may be missed, or at least not reliably
be detected [108–111]. Moreover, when comparing results
from diﬀerent technical platforms, consistency of data for
diﬀerentially expressed genes was often disappointing [111].
Part of the problem was that low abundance (and thereby
notreliably)detectedgenes,wereoftennotﬁlteredout[109].
Moreover, diﬀerentplatformsuseddiﬀerentprobesequences
for individual genes with the consequence of diﬀerent
binding characteristics of target genes. In recent years, eﬀorts
have been undertaken to optimize intra- and interplatform
consistency which may be reached by appropriate gene
ﬁltering and standardization and optimization of probe
sequences [110, 111].
As an important extension of DNA microarray technol-
ogy, technological platforms for large-scale protein (pro-
teome) analyses have been developed in recent years [14,
112]. In so-called antibody arrays, predeﬁned antibodies are
immobilized on a glass slide to interrogate a given protein
sample (e.g., a cellular lysate) [113]. In protein microarrays,
a complex protein mixture or individual predeﬁned proteins
are immobilized on a glass slide, which is then probed with
speciﬁc antibodies or patients’ sera. The detection lower
limit of protein concentrations using protein microarrays
is at a 10-cell equivalent. However, the most commonly
used technology for proteome analysis combines protein
separation by 2D-gel electrophoresis with mass spectrom-
etry. Current mass spectrometry may be performed with
high mass accuracy (<10 parts per million). Theoretically,
this is enough for the identiﬁcation of any protein in a
given sample. However, even with high resolution protein
separation, the number of proteins that may be identiﬁed is
generally less than 10000, out of an estimated one million.
Moreover, this method suﬀers from poor reproducibility and
lacks reliable quantiﬁcation.
A major challenge for large-scale gene and protein anal-
yses is data processing and biostatistics. Before microarray
data may be subjected to detailed analysis, preprocessing
of raw data must be performed [114]. This includes image
analysis, summarization, and normalization. In particular,
each microarray must be normalized to all other microarrays
of an experiment, so that all microarrays are comparable
[115]. Identiﬁcation of genes or gene patterns uses so-called
supervised and unsupervised methods. Supervised methods
are generally applied when a class label for each sample is
known, for example, when each sample may be attributed
to a deﬁned clinical or histopathological entity. Supervised
clustering methods may then identify diﬀerentially expressed
genes or may even predict the class label of a new unknown
sample. If there are no clearly deﬁned groups or subgroups,
unsupervised methods (clustering) may be applied. A series
of diﬀerent methods are used for cluster analysis, like k-
means clustering or hierarchical clustering, as described by
Eisen et al. [116].
Taken together, not unexpectedly, data generated by
genomics and proteomics technologies often need further
validation by an independent method, an independent clini-
calcohort,orbyotherexperimentalmodels.Fortunately,this
is more and more common in more recent studies. However,
there is indeed a series of reports, for example, from RA,
SLEandpsoriasis,whichshowthatgenepatternsmayindeed
be reproducible in independent studies. Overlapping results
may even be found between human and animal studies.
8. Candidates for Biomarkers Derived from
Genomicsand ProteomicsStudies
It is tempting speculate whether large-scale genomics or
proteomics studies might provide new clinical markers
for disease classiﬁcation, treatment response, or overall
prognosis. These might signiﬁcantly complement the use
of autoantibodies for diagnosis and subclassiﬁcation of
autoimmune diseases [117] .T h e r eh a v eb e e nas e r i e so f
studies particularly addressing this issue, but so far, none
of the proposed markers has reached clinical diagnostics
[112, 118]. However, there are some promising candidates.
As mentioned, a series of independent gene expression
proﬁling studies on SLE identiﬁed an interferon signature,
referring to a cluster of highly diﬀerentially expressed INF-
inducible genes in SLE compared with controls [47, 54–
56, 66–68]. These include IFIT1, IFI44, MX1, OAS1, OAS2,
and OASL. These might be promising candidates but their
potential as clinical markers has not been tested so far.
However, in the mentioned study by Bauer et al. [75],
who performed a serum proteome analysis of 160 diﬀerent
proteins to distinguish lupus patients from controls, and
inactive from active disease in a series of 30SLE patients,
dysregulated levels of 30 cytokines were identiﬁed [75].
Fifteen patients had high and 15 patients had low lev-
els of IFN-regulated transcripts, correlating with disease
activity. Some of the diﬀerentially expressed proteins, for
example, MCP-1 (CCL2), MIG (CXCL9), IP-10 (CCL10),
and I-TAC (CXCL11), might indeed serve as markers for
disease activity in SLE, because these were diﬀerentially
expressed between active and inactive disease, and not only
between SLE patients and controls. In a more recent study,
transcriptomes of puriﬁed monocytes from 9SLE patients
and 7 healthy controls were analyzed [119]. Sialic acid-
binding Ig-like lectin 1 (Siglec-1) was identiﬁed as one of
the most prominent candidate genes. As determined by ﬂow12 Mediators of Inﬂammation
cytometry, the frequency of Siglec-1 expressing monocyte
subsets correlated with disease activity. Authors suggested
that Siglec-1 expression in resident blood monocytes might
be a potential marker for monitoring of disease activity. By
use of a cytokine/chemokine antibody array it was shown
that urinary levels of VCAM-1, sTNFR-1, CXCL16, and P-
selectin correlated well with the degree of nephritis in SLE
patients [120].
Based on DNA microarray analyses from peripheral
blood cells, CD14, S100A8, and S100A12 might be disease
markers for RA. Upregulation of these has been described
in independent clinical studies [29, 30]. Moreover, the role
of CD14+ monocytes in RA pathology has been emphasized
in as earlier report [39]. Interestingly, S100A8, S100A12,
IL1B, and IL1R2 were highly expressed in PBMC of a
rat and murine model of CIA and were suggested as
markers for disease activity [121]. Interestingly, IL-17 has
not consistently been shown to be upregulated in peripheral
blood of RA patients and may thus not serve as marker for
early diagnosis or disease course, although it is expressed in
synovium and synovial ﬂuid of RA patients [9, 16, 122].
It is well known that levels of both TNF-α and IL-
6 are elevated in the serum and joints during active RA.
Expression of soluble TNF receptor II (sTNFRII) parallels
TNF-α levels and might thus be regarded as a surrogate
marker for inﬂammation in RA. A recent study included 170
patients from 3 large cohorts of US women, who had been
followed up for up to 12 years after blood collection [123].
Serum levels of sTNFRII were elevated up to 12 years prior
toRAsymptomsandwerepositivelyassociatedwithincident
RA. Thus, sTNFRII might serve as an early marker for RA
whichcouldhaveimplicationsforriskcounselingorforearly
intervention to prevent RA in patients at risk.
IL-17 might have a potential as marker for MS. As
mentioned above, MS patients with disease exacerbation had
3.5-times more IL-17 mRNA-positive mononuclear cells in
peripheral blood compared with patients in remission [83].
Thus, IL-17 levels may herald disease exacerbation, which
is often hard to verify based on clinical ﬁndings only. In
the mentioned treatment study on MS patients receiving
IFN-β treatment, gene expression in PBMC diﬀered between
responders, and nonresponders [34]. The vast majority
of genes regulated in ex vivo experiments in responders
was not regulated in the nonresponders. This included
t r a n s c r i p t sf o rI L - 8 ,I L - 1 7r e c e p t o r ,S T A T 1 ,a n dT R A I L .
Authors suggested that that the evaluation of the PBMC
response to treatment might eventually allow prediction of
long-termtreatmentresponse.However,alargerstudymight
be necessary to validate their ﬁndings. This is particularly
true in light of a more recent study by Sellebjerg et al. ,
which tried to identify genes that may predict treatment
eﬀects of IFN-β in MS patients [35]. In their analysis of
10 patients, authors found no predictive genes or gene
patterns.
In a study on early molecular events in SSc, COL7A1
and COL18A1 were found as putative biomarkers for early
onsetofSSc,bothupregulatedinﬁbroblastsfromuninvolved
skin lesions of SSc patients compared with controls [62].
A correlation between disease activity and serum COL18A1
Chronic inflammatory diseases
(rheumatoid arthritis, psoriasis . . .)
Cytokine patterns
Anti-TNF, IL-1 RA,
anti-IL-23,
anti-IL-15. . .
treatment
Figure 1: Development of new treatment modalities for chronic
inﬂammatory diseases based on cytokine or chemokine proﬁles.
levels has been described in SSc patients in an independent
study [103].
Together, there is indeed a series of candidate markers
for autoimmune diseases based on recent genomics and
proteomics studies, but larger and prospective studies are
needed to substantiate these ﬁndings.
9. Treatment andPerspectives
Treatment of autoimmune diseases has long been based
on the use of nonspeciﬁc anti-inﬂammatory drugs and the
induction of severe immunosuppression. This has changed
dramatically in the past years with the introduction of
neutralizing antibodies or soluble receptor molecules target-
ing inﬂammatory cytokines or immune cell receptors and
the use of tolerizing autoantigens, all of which speciﬁcally
downmodulate immune responses [6, 124, 125]( Figure 1;
Table 3).
Pioneering work in anti-cytokine therapy has been pub-
lished in the early seventies by Skurkovich et al. [70, 126]. In
elegant experiments, authors showed that lymphocytes from
mice immunized with L cells together with anti-interferon
serum showed signiﬁcantly reduced cytotoxicity for targets
cells compared with mice that had received control serum.
Similarly, sera from immunized mice showed no cytotoxic
activity, when mice were immunized together with anti-
interferon serum. Shortly thereafter, it was shown that IFN-α
serum levels were elevated in patients with diﬀerent autoim-
mune diseases such as SLE and RA [69]. Subsequently, in
1975–1977, the ﬁrst clinical trials of anticytokine therapy
were conducted using antibodies to IFN-α in patients with
acuteRA.Asigniﬁcantreductioninjointpain,inﬂammation
a n de d e m aw a sa c h i e v e d[ 70].
Later on, a major breakthrough was the observation
that expression of proinﬂammatory cytokines IL-1, IL-
6, IL-8, and GM-CSF, produced by synoviocytes isolated
from RA patients, could be blocked by addition of a TNF
neutralizing antibody [127]. Therapeutic biological agents
thatneutralizedTNFwereappliedsoonthereafterinhumans
for RA and a variety of other chronic inﬂammatory diseases
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Table 3: Biologic drugs targeting cytokines or cytokine receptors in human autoimmune diseases
Disease Therapeutic agent Number of patients ∗ Trial design References
RA
Anti-TNF (inﬂiximab) 73 Phase III [128]
Anti-TNF (inﬂiximab) 428 Phase III [129]
Soluble TNF p75 receptor (etanercept) 180 Phase III [130]
Human anti-TNF (adalimumab) 120 Phase III [131]
IL-1RA (anakinra) 472 Phase III [132]
IL-1RA (anakinra) plus etanercept vs. etanercept alone 244 Phase III [133]
Fusion protein of IL-1RI and IL-1RAcP (IL1-trap) 200 Phase II Not published so far;
see also [134]
IL-6 inhibitor (Tocilizumab) versus placebo 359 Phase II [135]
IL-6 inhibitor (Tocilizumab) versus DMARD 306 Phase III [136]
IL-6 inhibitor (Tocilizumab) versus placebo 623 Phase III [137]
IL-6 inhibitor (Tocilizumab) versus placebo 1,220 Phase III [138]
IL-15 inhibitor (HuMax-IL-15 versus placebo 30 Phase I-II [139]
SOJIA∗∗ IL-6 inhibitor (Tocilizumab) versus placebo 56 Phase III [140, 141]
SLE IL-1RA (anakinra) 4 Phase II [142]
Psoriasis
Anti-TNF (inﬂiximab) 378 Phase III [143]
Soluble TNF p75 receptor (etanercept) 618 Phase III [144]
Human anti-TNF (adalimumab) 271 Phase III [145]
Human anti-IL12/23 (ustekinumab) 766 Phase III [146, 147]
Human anti-IL12/23 (ustekinumab) 1203 Phase III [146, 148]
Psoriatic arthritis
Soluble TNF p75 receptor (etanercept) 60 Phase III [149]
Human anti-TNF (adalimumab) 313 Phase III [150]
MS Anti-VLA-4 (natalizumab) 213 Phase III [151]
∗Number of patients refers to the total number in the treatment and placebo groups.
∗∗SOJIA, systemic-onset juvenile idiopathic arthritis.
In an early clinical trial for treatment of patients with
long-standing RA which was refractory to other treatments,
the humanized anti-TNF antibody inﬂiximab was used
[128]. Interestingly, synergistic eﬀects were observed in
combination therapy with methotrexate, which is commonly
used for RA treatment. Subsequently, many companies
developed TNF blockers for a variety of diﬀerent diseases
such as RA, psoriasis, inﬂammatory bowel disease, and
multiple sclerosis [6]. Interestingly, a combination of both
anti-TNFtherapywithatolerogenicCD4antibodywasmore
eﬀective in CIA than each compound alone, suggestive for a
superioractivityofacombinationtherapy,whichmighthave
implications for future treatment approaches in humans
[152]. However, for as yet unknown reasons some patients
within each disease group do not respond to treatment with
biological compounds and anti-TNF treatment increases the
risk for development of infectious diseases and the relapse
of latent tuberculosis. Moreover, production of anti-nuclear
antibodies is often observed, a ﬁnding with still unknown
relevance for the pathogenesis of autoimmunity in diseases
like psoriasis and RA [127]. In the future, a major challenge
will therefore be the selection of patients for individualized
treatments based on predictive genetic markers or genomic
gene patterns, together with a reduction of unwanted side
eﬀects.
Beside TNF, other cytokines such as IL-1, IL-6, and
IL-15 have emerged as putative targets for treatment of
autoimmune diseases and in particular of RA (Table 3).
IL-1 receptor antagonist (IL-1Ra) acts as a natural IL-1
inhibitor preventing the interaction of IL-1 with its cell
surface receptors. The corresponding biological compound,
anakinra, which mimicks the IL-1Ra eﬀect has been used
in clinical trials, but with variable and often limited success
[125]. In a double-blind, multicenter, randomized, placebo-
controlledtrialonRApatients,subcutaneousadministration
of anakinra was more eﬃcacious than placebo. However, a
combination with etanercept, a soluble TNF receptor which
competes for TNF receptor binding, was not better than
etanercept alone [132, 133]. Overall, it appears that anakinra
isanonlymodestinhibitor ofRApathology.Butinsystemic-
onset juvenile idiopathic arthritis (SOIJA) and adults Still’s
disease, anakinra showed signiﬁcant improvement [140].
Using a fusion protein which contains extracellular binding
motifs of the IL-1RI and IL-1 receptor accessory protein
(IL-1RacP) coupled to the Fc fraction of the human
immunoglobulin G, called IL-1 trap, a multicenter trial was
performed on 200 RA patients. But results of this trial have
not been published so far. Further clinical trials are currently
underway with a monoclonal anti-IL-1RI antibody, which14 Mediators of Inﬂammation
might help to support the role of IL-1 targeting agents in dif-
ferent immune-mediated inﬂammatory diseases such as RA.
IL-6 is a major B-cell-stimulatory factor involved in
antibody production. IL-6 also participates in diﬀerentiation
of T cells into the Th17 lineage. As mentioned above, IL-
17 plays a central role in diﬀerent models of autoimmune
diseases. A humanized version of an anti-IL-6 receptor
monoclonal antibody, termed tocilizumab (TCZ),wasdevel-
oped to block IL-6 receptor binding and has been tested
in a series of clinical phase III trials as a potential new
treatmentforRA[135–138].IntheSAMURAItrial,TCZwas
successful in the reduction of joint damage of RA patients
[136]. In the TOWARD study, TCZ was combined with
conventional DMARDs and signiﬁcantly improved disease
activity compared with conventional DMARDs alone, as
determinedbyACR(AmericanCollegeofRheumatology)50
response [138]. In clinical trials with children suﬀering from
SOIJA, TCZ signiﬁcantly reduced clinical symptoms [141].
Because of these promising results, TCZ is close to being
approved for RA treatment in Europe, and clinical trials with
TCZareinprogressforotherautoimmunediseasessuchSLE.
IL-15 is a 14-15 kDa protein and member of a cytokine
family with structural similarities to IL-2. It stimulates the
proliferation of CD4+ and CD8+ T cells and CD40L-treated
B cells, and induces the generation and persistence of NK
cells and the production of immunoglobulin M [153]. IL-
15 exerts protective eﬀects against apoptosis. Moreover, it
is critically involved in Th1 and Th17 polarization and it
induces eﬀector functions in mast cells, neutrophils, NK
cells,Bcells,macrophagesandDCs.IL-15isdetectableinthe
serum of patients with ulcerative colitis and psoriatic lesions
express signiﬁcant levels of IL-15. It can also be detected
in the serum and synovial membrane of patients with
RA. A soluble fragment of the mouse IL-15Rα signiﬁcantly
reduced the severity of CIA [111] .M o r e o v e r ,af u l l yh u m a n
monoclonal antibody against IL-15 has shown promising
results in the treatment of RA patients [139].
More recently, an human and mouse chimeric anti-
CD20 antibody termed rituximab, which causes depletion
B lymphocytes, has been used for treatment of B-cell
lymphomas, Wegener’s granulomatosis, dermatomyositis,
RA, SLE and cutaneous autoimmune bullous diseases, with
considerable clinical response rates [154, 155]. However,
although signiﬁcant B-cell depletion was achieved by this
treatment, circulating immunoglobulin levels did often not
change signiﬁcantly, and treatment eﬀects did not corre-
late with autoantibody titers in a signiﬁcant portion of
SLE patients [155]. The latter ﬁndings might argue for a
mechanism of anti-CD20 antibodies beyond suppression of
immunoglobulin production, for example, via inhibition of
antigen presentation.
Development of biologics also had a profound inﬂuence
on treatment of psoriasis [156]( Table 3). Earlier reports
demonstrated that the TNF inhibitor etanercept, which has
shown eﬃcacy in the treatment of RA, also worked in
psoriatic arthritis [149]. In that randomised, double-blind,
placebo-controlled trial, 25mg etanercept or placebo were
administered twice-weekly by subcutaneous injections in
60 patients with psoriatic arthritis and psoriasis. The vast
majority of etanercept-treated patients met the Psoriatic
Arthritis Response Criteria (PsARC), compared with only
about 20% of placebo patients. The ACR20 was achieved by
morethan70%ofetanercept-treatedpatientscomparedwith
about 10% of placebo-treated patients. A signiﬁcant number
of etanercept-treated patients achieved a 75% improvement
in the Psoriasis Area and Severity Index (PASI), compared
with none of the placebo-treated patients. Together, etaner-
cept was an eﬃcacious treatment for both psoriatic arthritis
and psoriasis.
The human anti-TNF monoclonal antibody adali-
mumab, was evaluated for treatment of active psoriatic
arthritis (PsA) in a more recent trial [150]. Patients
with moderately to severely active PsA received 40mg
adalimumab or placebo subcutaneously every other week.
Overall, 58% of the adalimumab-treated patients achieved
an ACR20 response at week 12, compared with 14% of
the placebo-treated group. Signiﬁcant improvement was
also achieved in structural joint damage. Two third of the
patients achieved a 75% PASI improvement response at
24 weeks, compared with only 1% of the placebo group.
Overall, adalimumab was safe and well tolerated. Together,
adalimumab had a signiﬁcant impact on both joint and skin
manifestations in patients with moderate to severe PsA.
These ﬁndings were signiﬁcantly extended by the
CHAMPION study, where adalimumab was compared with
methotrexate, a classical systemic agent for psoriasis, to
further deﬁne the role of biologics in psoriasis [145].
Overall108patients withmoderateto severeplaquepsoriasis
were randomized to adalimumab (80mg subcutaneously at
week 0, then 40mg every other week), 110 patients were
randomized to methotrexate and 53 to placebo. PASI 75 as
the primary endpoint of the study at 16 weeks was reached
by 79.6% of adalimumab-treated patients, compared with
35.5% for methotrexate, and 18.9% for placebo. Together,
adalimumab demonstrated signiﬁcantly higher eﬃcacy in
psoriasis than methotrexate.
In a phase III, multicentre clinical trial 378 patients
with moderate-to-severe plaque psoriasis were treated with
inﬂiximab for 46 weeks [143]. At week 24, placebo-treated
patients crossed over to inﬂiximab treatment. In this trial,
80% of patients treated with inﬂiximab achieved at least a
75% improvement from their baseline PASI score, compared
with 3% in the placebo group. Overall, inﬂiximab was well
tolerated in the majority of patients.
Based on recent observations, IL-12 and IL-23 appear
to play important roles in psoriasis pathophysiology [95,
97, 146]. In a phase III double-blind, placebo-controlled
study (PHOENIX 1 trial), 766 patients with moderate-
to-severe psoriasis received human anti-IL12/23 antibody
ustekinumab [147]. More than two third of the patients
receiving ustekinumab achieved signiﬁcant improvement
as determined by PASI 75 at week 12, compared with
3% receiving placebo. Of patients achieving long-term
response, half of them were either assigned to maintenance
ustekinumab or withdrawal. Expectedly, PASI 75 response
was better maintained in those receiving maintenance ustek-
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treatment. Serious adverse events occurred in about 1% of
510 patients receiving ustekinumab. Together, ustekinumab
was eﬃcacious and save for the treatment of moderate-to-
severe psoriasis. Interestingly, the dosing scheme with an
application every 12 weeks appeared to be eﬃcacious for at
least a year.
A parallel slightly modiﬁed trial assessed the eﬃcacy and
safety of ustekinumab in psoriasis patients and assessed the
eﬀects of dosing intensiﬁcation in so-called partial respon-
ders (PHOENIX 2 trial; [148]) . In this multicentre, phase
III, double-blind, placebo-controlled study, 1230 patients
with moderate-to-severe psoriasis were assigned to receive
ustekinumab 45mg or 90mg at weeks 0 and 4, then every
12 weeks, or placebo. Partial responders were rerandomised
at week 28 to continue dosing every 12 weeks or escalate to
dosing every 8 weeks. More partial responders at week 28
who received ustekinumab 90 mg every 8 weeks achieved
PASI 75 at week 52 than did those who continued to receive
the same dose every 12 weeks. Serious adverse events again
were as low as 1-2% in all groups. Authors concluded
that intensiﬁcation of dosing to once every 8 weeks with
ustekinumab 90mg might be necessary to achieve a full
response.
Finally, the use of autoantigens as tolerizing drugs has
been successful in diﬀerent experimental systems of murine
insulin-dependent diabetes and experimental autoimmune
encephalomyelits [157, 158]. However, although, encourag-
ing results were obtained in phase I and phase I/II trials
in patients with multiple sclerosis, RA or uveitis, larger
controlledstudies could not conﬁrmthese results [125]. This
might be due to wrong dosage used in the clinical trials
or treatment of advanced stages when irreversible lesions
had already developed, beside other as yet unknown factors.
However, also recent-onset treatment in type-1 diabetes was
not successful. Large controlled trials conducted using oral
insulin to prevent or even treat recent onset type-1 diabetes
were also negative [159]. But ongoing studies on MS and
type-1 diabetes with diﬀerent regimens might clarify this
situation. It might well be the case that antigen therapy alone
might be insuﬃcient to arrest ongoing disease, but should
be complemented by therapies targeting T-cell receptors or
cytokines like TNF.
Taken together, recent progresses in cytokine research
and the rapid development of speciﬁcally targeting bio-
logic agents will open interesting perspectives for patients
suﬀering from various chronic inﬂammatory diseases in
the near future. In this context, it is of particular interest
that pathogenic mechanisms often overlap between diﬀerent
diseases, which might even foster the development of new
treatment modalities.
Abbreviations
CD: Crohn’s disease
CIA: collagen-induced arthritis
EAE: experimental allergic encephalitis
MNC: mononuclear cells
MS: multiple sclerosis
OA: osteoarthritis
PASI: Psoriasis Area and Severity Index
PBMC: peripheral blood mononuclear cells
RA: rheumatoid arthritis
SLE: systemic lupus erythematosus
SSc: systemic sclerosis.
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